A court trims but does not dismiss Lilly's case against compounder Empower

A federal judge has thrown out part of Eli Lilly's lawsuit against Empower Pharmacy, but has allowed other parts of the case to continue, according to a report on the ruling.^[1] The lawsuit centers on claims that Empower misled customers about its compounded versions of tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound.^[1]

The case is one of several legal fights Lilly has waged against compounding pharmacies that sell copies of its GLP-1 drugs.^[1] The source describing the ruling notes it is the longest-running of these compounding suits, though the specific claims that were dismissed, the claims that survive, and the court's reasoning are not detailed in the available reporting.^[1] The full text explaining the judge's decision sits behind a paywall, so the exact legal grounds for the partial dismissal are not yet known from what is available here.^[1]

Compounded versions of tirzepatide and semaglutide became widely available over the past few years as pharmacies used a federal allowance for compounding drugs that are in short supply. Once the Food and Drug Administration removed tirzepatide and semaglutide from its shortage lists, Lilly and Novo Nordisk, the maker of Ozempic and Wegovy, began suing compounders and telehealth companies that continued selling copycat versions. This case against Empower is part of that broader legal campaign.^[1]

Why it matters for patients

For people currently using compounded tirzepatide from Empower or a similar pharmacy, this ruling does not end the underlying legal dispute. Some of Lilly's claims were dismissed, but others are moving forward, meaning the case is still active and the final outcome is not settled.^[1] Patients relying on compounded products should understand that the legal status of these medications remains contested, and the details of what a court will ultimately decide about their marketing, safety claims, or availability are not resolved by this ruling.^[1]

The ruling also does not, based on the available reporting, say anything about whether Empower's compounded tirzepatide will remain on the market, change in price, or face new restrictions. Those practical questions are not addressed in the source describing the decision, so patients should not assume the ruling changes access to compounded products one way or the other right now.^[1]

More broadly, this case reflects the ongoing tension between brand-name drugmakers and the compounding industry over GLP-1 medications. As FDA shortage designations for tirzepatide and semaglutide have shifted, so has the legal landscape for compounders, and outcomes in cases like this one may eventually shape which compounded products stay available and under what conditions. But that broader shift is not something this particular ruling settles by itself, according to the available reporting.^[1]

What happens next

The available reporting does not include a schedule for further proceedings, a trial date, or next steps in the litigation.^[1] Because the case is described as ongoing, with some claims still active, further rulings or a trial could follow, but no dates are specified in the source.^[1] Readers watching this case for its effect on the availability or marketing of compounded tirzepatide will need to wait for additional reporting on what claims specifically survived and what the judge's reasoning was, none of which is detailed in what is available here.^[1]